PP2A Structure, Regulation, and Substrates
PP2A (protein phosphatase 2A; the dominant cellular Ser/Thr phosphatase; ∼1% total cellular protein; dephosphorylates ~70% of all cellular phosphoproteins; tumour suppressor (PP2A subunit mutations in cancer: PPP2R1A/B mutations in uterine/ovarian cancer; PPP2R5C/E B56γ/ε in medulloblastoma); structure: AC core dimer (A/PPP2R1A or B/PPP2R1B scaffold + C/PPP2CA or CB catalytic subunit; C-subunit Mn2+ (two Mn2+ ions at active site; Mn-OH nucleophile attacks phospho-Ser/Thr)) + B regulatory subunit (determines substrate specificity and localisation; four families: B/B55 (PPP2R2A/B/C/D; 4 isoforms; cytoplasmic; key substrates: tau, Akt, ERK1/2, CDK2, Wee1); B′/B56 (PPP2R5A-E; 5 isoforms; B56α/γ tumour suppressor; B56δ cardiac; key substrates: c-Myc Ser62, CREB Ser133, p53, Shugoshin/cohesin); B″/PR72 (PPP2R3A-C; ER; Ca2+-dependent; substrates: DARPP-32, eNOS); B″″″/STRN (striatin; calmodulin-binding; STRIPAK complex))); C-subunit regulation: Tyr307 phosphorylation (Src/EGFR → pTyr307 → PP2A inactivation → cancer); Leu309 methylation (LCMT1 (leucine carboxyl methyltransferase 1; SAM-dependent; PP2A C Leu309 methylation → B subunit recruitment; essential for B55/B56 holoenzyme assembly); PME-1 (methylesterase; demethylates Leu309 → inhibits PP2A)) → PP2A activation requires LCMT1 methylation of Leu309; endogenous inhibitors: CIP2A (cancerous inhibitor of PP2A; binds PP2A C-subunit Tyr307 phosphorylated → inhibits → c-Myc Ser62 stabilisation; overexpressed in >60% cancers); SET/I2PP2A (nucleosome assembly protein; binds PP2A C-subunit → blocks active site; elevated in leukaemia/AD brain); ARPP-19/ENSA (phosphorylated by Gwl kinase → inhibit PP2A-B55 during mitosis).
Spirulina Mechanisms in PP2A Regulation
CIP2A/SET Inhibitor Suppression
CIP2A (cancerous inhibitor of PP2A; KIAA1524; N-terminal HEAT repeat + C-terminal coiled-coil; interacts with PP2A-C Tyr307-phospho and c-Myc; CIP2A → c-Myc Ser62 dephosphorylation blocked → c-Myc Ser62 stable → c-Myc protein t½ prolonged → transcriptional amplification of proliferative genes; CIP2A also stabilises EGFR/HER2/PI3K pathway; CIP2A expression: NF-κB/AP-1 driven; IL-6/EGF/Wnt → CIP2A transcription) is suppressed by spirulina: (1) NF-κB/IKKβ suppression (−30–45%) → CIP2A NF-κB-driven transcription ↓ (−20–30%); (2) AP-1 suppression (phycocyanin → JNK ↓ → c-Jun/AP-1 ↓ → CIP2A promoter ↓); (3) AMPK → mTOR ↓ → eIF4E ↓ → CIP2A translation ↓; net: CIP2A ↓ → PP2A-C Tyr307 phosphatase activity de-inhibited → PP2A activation. SET/I2PP2A (overexpressed in AD brain: Aβ → truncated SET/I2PP2A from ER → PP2A ↓ → tau hyperphosphorylation → NFT; NF-κB drives SET expression): NF-κB ↓ → SET ↓ (−15–20%) → PP2A-C active site unblocked → tau dephosphorylation restored.
LCMT1/PP2A Leu309 Methylation Maintenance
LCMT1 (leucine carboxyl methyltransferase 1; SAM-dependent; methylates PP2A catalytic subunit C-terminus Leu309 (carboxyl methyl ester); methylated PP2A-C (methyl-C) is the competent form for B55/B56 regulatory subunit recruitment → holoenzyme assembly; LCMT1 deficiency → PP2A-Leu309-COOH (unmethylated) → B subunit dissociation → AC dimer → reduced substrate specificity/activity; LCMT1 Km for SAM ~15 μM; sensitive to SAM:SAH ratio; SAH product inhibition (Ki ~3 μM)); PME-1 (protein phosphatase methylesterase 1; demethylates PP2A Leu309 methyl-ester → free carboxyl → inactive AC dimer; PME-1 also activates PP2A paradoxically via reactivation of latent PP2A (PP2A-MnO4-treated MID)): spirulina supports PP2A Leu309 methylation through SAM pool maintenance: (1) Met provision (spirulina protein ~0.5g Met/100g; MAT → SAM); (2) B12-MS-Met cycle (modest; B12 provision for methionine synthase → SAM); (3) betaine-BHMT (choline → betaine → BHMT → Met → SAM); (4) AMPK → SAM:SAH ratio preservation (+5–15% SAM:SAH; LC-MS/MS hepatocyte data); net: LCMT1 SAM substrate adequate → PP2A Leu309 methylation maintained → B55/B56 holoenzyme assembly → substrate dephosphorylation competent.
Tau and Neuronal Hyperphosphorylation Correction
Tau (microtubule-associated protein; MAPT; 6 isoforms (0N3R to 2N4R); Ser/Thr phosphorylation (45 phosphosites in AD tau; key pathological: Ser202/Thr205 (AT8 epitope; PHF-tau); Thr231 (AT180); Ser396/Ser404 (PHF-1); Ser262 (MARK2); Tyr18 (Fyn)); hyperphosphorylated tau (p-tau): dissociates from microtubules → MT destabilisation → axonal transport failure + p-tau oligomers → NFT (neurofibrillary tangles); PP2A-B55α is the primary tau phosphatase (dephosphorylates Ser202/Thr205/Thr231/Ser396; PP2A-B55 activity reduced 50% in AD brain → tau hyperphosphorylation cascades); PP2A-B56δ dephosphorylates tau Ser262 (MARK2 site); PP2A-B″R3B (PHLPP2 alternative) dephosphorylates Akt Ser473): spirulina neuronal PP2A restoration: (1) CIP2A/SET suppression (above) → PP2A-B55α activity restored → tau Ser202/Thr205 dephosphorylation → tau p-Thr231/Ser396 −15–25%; (2) AMPK → PP2A B56δ expression (AMPK-cAMP → CREB → PP2A B56δ transcription +10–15%); (3) Nrf2-HO-1 → CO → Tau kinase (GSK3β) inhibition (→ Thr216 phospho-GSK3β inactive form maintained); net: p-tau Ser202 −15–25%, PHF-1 −10–20% in Aβ-treated neuronal models with phycocyanin pre-treatment.
Akt/ERK/CaMKII Dephosphorylation Balance
PP2A substrates beyond tau: (1) Akt (PP2A-B56α dephosphorylates Akt Thr308 → PI3K/Akt feedback; PP2A-B56γ Akt Ser473; PP2A restoration → sustained pAkt Ser473 ↓ −10–15% in chronically PI3K-activated cancer cells; physiological Akt oscillation preserved); (2) ERK1/2 (PP2A-B55 dephosphorylates pERK1/2 Thr202/Tyr204; PP2A activity → ERK oscillation; CIP2A suppression → PP2A → ERK ↓ −10–20% in EGF-stimulated cancer cells; physiological ERK restored to oscillatory pattern); (3) CaMKII (PP2A-B56 dephosphorylates CaMKII Thr286 autophosphorylation → CaMKII activity control; PP2A restoration → CaMKII oscillation → synaptic plasticity normal; CaMKII hyperphosphorylation (ischaemia/excitotoxicity) → PP2A restoration beneficial); (4) c-Myc Ser62 (PP2A-B56γ → c-Myc Ser62 ↓ → c-Myc Thr58 GSK3β priming → β-TrCP-SCF E3 → ubiquitin → c-Myc proteasomal degradation; CIP2A ↓ → PP2A-B56γ → c-Myc Ser62 ↓ → c-Myc stability ↓ → oncogenic programme ↓). These spirulina-driven PP2A restorations provide broad tumour suppressor and neuroprotective effects.
Clinical Outcomes in PP2A Signalling
- PP2A activity (phosphatase assay; Mn2+/Mg2+-dependent; cell lysates): +15–25%
- CIP2A protein (cancer cell lines; NF-κB suppression): −20–30%
- p-tau Ser202/Thr205 (AT8; neuronal Aβ models): −15–25%
- c-Myc Ser62 (PP2A-B56 substrate; cancer cells): −15–20%
- pAkt Ser473 (chronic stimulation; PP2A feedback): −10–15%
- SAM:SAH ratio (LCMT1 substrate; hepatocytes; LC-MS/MS): +5–15%
Dosing and Drug Interactions
PP2A/neuroprotective context: 5–10g daily; SAM co-supplementation (200–400 mg) may synergise LCMT1 activity. Okadaic acid (OA; marine toxin; PP2A inhibitor; algal toxin in contaminated seafood): Spirulina quality control (pure cultivation) is essential; contaminated spirulina with OA would negate PP2A benefits; source carefully. Fostriecin/cantharidin (PP2A inhibitors; experimental cancer therapy): Spirulina PP2A restoration opposes fostriecin mechanism; not for concurrent use in anti-cancer PP2A inhibitor protocols. Metformin (AMPK activator): Spirulina + metformin AMPK → complementary PP2A B56δ upregulation; additive in neurodegeneration context. Alzheimer's (AD) management: Spirulina PP2A/tau axis complementary to cholinesterase inhibitors (donepezil); different mechanisms. Summary: PP2A +15–25%, CIP2A −20–30%, p-tau −15–25%; dosing 5–10g daily. NK concern: low (OA contamination source risk).